Celltrion Healthcare Co.,Ltd.

Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines through an extensive global network that spans more than 110 different countries. Celltrion Healthcare provides REMSIMA, the world's first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of autoimmune disease, and innovative biopharmaceutical medications to help increase patient access to advanced therapies around the world. For additional information on our guidelines, please visit: https://bit.ly/3QyOyt7

成立年份

1999

員工

2,400+

行業

製藥產業

公司類型

Public Company

股票

ksc: 068270.KS

總部

🇰🇷4f, 19, Academy-ro 51, Yeonsu-gu, Incheon, Korea 22014, Incheon, 406-081, Kr (+2)